RELATED STUDY
Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome
Key Findings: Subjects with irritable bowel syndrome (IBS), both diarrhea-type or alternating constipation and diarrhea, were given dronabinol or placebo. The group receiving dronabinol had less gut motility with fasting compared to the placebo group. Also noted are the possible role of fatty acid amide hydrolase (FAAH) and CNR1 gene variants could have on colonic motility and response to dronabinol.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 75
Study Result: Positive
Research Location(s): United States
Year of Pub: 2011
Cannabinoids Studied: Tetrahydrocannabinol (THC), Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Pharma THC
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype I
Receptors Studied: CB1, CB2, GPCR, CB1 agonist, CB1 antagonist, CB2 agonist, CB2 antagonist
Ligands Studied: Acetylcholine
Dosage: Dronabinol (2.5-5mg)
Route of Administration: Oral (Ingestion)
Citation: Wong BS, et al. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology. 2011; 141:1638-47.e1-7. doi: 10.1053/j.gastro.2011.07.036
Authors: Wong BS, Camilleri M, Busciglio I, Carlson P, Szarka LA, Burton D, Zinsmeister AR
